European Journal of Cancer
Journal Abbreviation: Eur. J. Cancer
ISSN: 0959-8049
eISSN: 1879-0852
Publisher: Elsevier
Publications (114)
High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma (2024)
Klümper N, Cox A, Eckstein M, Kuppe C, Ritter M, Brossart P, Luetkens J, et al.
Journal article
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis (2024)
Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, Barrios C, et al.
Journal article
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors (2024)
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, et al.
Journal article
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB (2024)
Amaral T, Nanz L, Stadler R, Berking C, Ulmer A, Forschner A, Meiwes A, et al.
Journal article
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer (2024)
Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, et al.
Journal article
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. (2024)
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, et al.
Journal article
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp (2023)
Hassel JC, Berking C, Forschner A, Gebhardt C, Heinzerling L, Meier F, Ochsenreither S, et al.
Journal article
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study (2023)
Lodde GC, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Hauschild A, et al.
Journal article
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419) (2023)
Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, et al.
Journal article
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG (2023)
Zaremba A, Mohr P, Gutzmer R, Meier F, Pföhler C, Weichenthal M, Terheyden P, et al.
Journal article